PMID- 28926469
OWN - NLM
STAT- MEDLINE
DCOM- 20180720
LR  - 20231115
IS  - 1536-7355 (Electronic)
IS  - 1076-1608 (Linking)
VI  - 23
IP  - 8
DP  - 2017 Dec
TI  - A Survey of Glucocorticoid Adverse Effects and Benefits in Rheumatic Diseases: 
      The Patient Perspective.
PG  - 416-420
LID - 10.1097/RHU.0000000000000585 [doi]
AB  - OBJECTIVE: The aim of this study was to explore, from the patient's perspective, 
      the beneficial and adverse effects (AEs) of glucocorticoids (GCs) in patients 
      with rheumatic diseases, to be used in the development of a patient-reported 
      outcome measure. METHODS: A cross-sectional survey, capturing benefits and AEs of 
      GC use, was administered to 2 groups of patients: (1) those attending a tertiary 
      rheumatology clinic with various rheumatic diseases who had used GCs within the 
      past year and (2) patients from the Hospital for Special Surgery rheumatoid 
      arthritis database. RESULTS: Cohort 1 had 55 GC users, and cohort 2 had 95 GC 
      users and 29 nonusers. The majority of GC users in both cohorts reported at least 
      1 AE (100%, 86%). The AE prevalence per person was 50% higher in cohort 1 
      compared with GC users in cohort 2 (7.7 vs. 5.3; AE ratio, 1.5; 95% confidence 
      interval, 1.3-1.7) and 2-fold greater in cohort 2 GC users compared with GC 
      nonusers (5.3 vs. 2.6; AE ratio, 2.0; 95% confidence interval, 1.6-2.6). In both 
      cohorts, AEs identified as "worst" by GC users included skin thinning/easy 
      bruising, sleep disturbance, mood disturbance, and change in facial shape. Most 
      felt GCs helped their disease "a lot" (78%/62%) and that the benefits were 
      greater than the AEs (55%/64%). Many AEs were more frequent in GC users than in 
      nonusers. CONCLUSIONS: Patients receiving GC therapy for rheumatic conditions 
      report a large number of AEs and those that have the greatest life impact are 
      often difficult for physicians to measure. These results will inform the 
      development of a patient-reported outcome measure to capture the effects of GCs 
      from the patient's perspective.
FAU - Black, Rachel J
AU  - Black RJ
FAU - Goodman, Susan M
AU  - Goodman SM
FAU - Ruediger, Carlee
AU  - Ruediger C
FAU - Lester, Susan
AU  - Lester S
FAU - Mackie, Sarah L
AU  - Mackie SL
FAU - Hill, Catherine L
AU  - Hill CL
LA  - eng
GR  - MR/N011775/1/MRC_/Medical Research Council/United Kingdom
GR  - NIHR-CS-012-016/DH_/Department of Health/United Kingdom
PT  - Journal Article
PL  - United States
TA  - J Clin Rheumatol
JT  - Journal of clinical rheumatology : practical reports on rheumatic & 
      musculoskeletal diseases
JID - 9518034
RN  - 0 (Glucocorticoids)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Australia
MH  - Cross-Sectional Studies
MH  - *Drug-Related Side Effects and Adverse 
      Reactions/classification/epidemiology/etiology
MH  - Female
MH  - *Glucocorticoids/administration & dosage/adverse effects
MH  - Humans
MH  - Male
MH  - Medication Therapy Management
MH  - Middle Aged
MH  - Patient Preference
MH  - Patient Reported Outcome Measures
MH  - *Rheumatic Diseases/drug therapy/psychology
MH  - United States
EDAT- 2017/09/20 06:00
MHDA- 2018/07/22 06:00
CRDT- 2017/09/20 06:00
PHST- 2017/09/20 06:00 [pubmed]
PHST- 2018/07/22 06:00 [medline]
PHST- 2017/09/20 06:00 [entrez]
AID - 10.1097/RHU.0000000000000585 [doi]
PST - ppublish
SO  - J Clin Rheumatol. 2017 Dec;23(8):416-420. doi: 10.1097/RHU.0000000000000585.